IGC Pharma (IGC) Operating Margin (2010 - 2025)
IGC Pharma's (IGC) quarterly Operating Margin came in at 1517.8% in Q3 2025, down 109062.0% year-over-year from N/an in Q3 2024, and down 201.0% quarter-over-quarter from 504.26% in Q2 2025.
Powered by 
Analysis
IGC Pharma (IGC) Operating Margin (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Operating Margin for 16 consecutive years, with 1517.8% the latest figure, recorded in Q3 2025.
- On a quarterly basis, Operating Margin fell 109062.0% year-over-year to 1517.8% in Q3 2025; TTM through Sep 2025 was 662.12%, a 12605.0% increase from a year earlier, with the FY2026 full-year figure at 775.39%, down 18956.0% from the prior year.
- Operating Margin was 1517.8% for Q3 2025 at IGC Pharma, down from 504.26% in the prior quarter.
- Over five years, Operating Margin peaked at 385.41% in Q2 2023 and troughed at 7764.29% in Q3 2021.
- A 5-year average of 1825.05% and a median of 1231.68% in 2022 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin plunged 642349 bps in 2021 and soared 653260 bps in 2022, its largest moves.
- Over 5 years, Operating Margin stood at 1679.58% in 2021, then jumped by 59 bps to 686.14% in 2022, then tumbled by 114 bps to 1469.61% in 2023, then surged by 50 bps to 730.74% in 2024, then sank by 108 bps to 1517.8% in 2025.
- The last three Operating Margin figures came in at 1517.8% (Q3 2025), 504.26% (Q2 2025), and 428.18% (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | IGC Pharma | 27.77 Mn | 27.51 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -1,517.80% |
| Jun 30, 2025 | -504.26% |
| Mar 31, 2025 | -428.18% |
| Dec 31, 2024 | -730.74% |
| Sep 30, 2024 | -427.18% |
| Jun 30, 2024 | -880.88% |
| Mar 31, 2024 | -735.59% |
| Dec 31, 2023 | -1,469.61% |
| Sep 30, 2023 | -856.01% |
| Jun 30, 2023 | -385.41% |
| Mar 31, 2023 | -2,433.13% |
| Dec 31, 2022 | -686.14% |
| Sep 30, 2022 | -1,231.68% |
| Jun 30, 2022 | -1,321.70% |
| Mar 31, 2022 | -5,328.69% |
| Dec 31, 2021 | -1,679.58% |
| Sep 30, 2021 | -7,764.29% |
| Jun 30, 2021 | -2,849.35% |
| Mar 31, 2021 | -3,445.68% |
| Dec 31, 2020 | -2,153.70% |